According to Mediclinic International's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.8378. At the end of 2022 the company had a P/E ratio of 15.2.
Year | P/E ratio | Change |
---|---|---|
2022 | 15.2 | -45.49% |
2021 | 28.0 | -547.12% |
2020 | -6.26 | -51.36% |
2019 | -12.9 | 102.7% |
2018 | -6.35 | -133.91% |
2017 | 18.7 | -30.62% |
2016 | 27.0 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.